Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.

Haase CL, Serratore Achenbach MG, Lucrezi G, Jeswani N, Maurer S, Egermann U

Obesity facts20 Aug 2021Cited by 33 (Europe PMC)

PMID34515194PMCIDPMC8546436DOI10.1159/000518325PepBankPUB-34515194

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity in a Swiss clinic, mean body weight fell by 4.1 kg (4.2%) at 7 months from baseline in the full cohort on liraglutide 3.0 mg.
In plain wordsIn adults with obesity in a Swiss clinic, body weight fell by an average of 4.1 kg after 7 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 7 months, full cohort
Study
n = 277
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 7 monthsAs given in this study (human).
Measurements
Weight change
−4.1 kg
full cohort, 7 months
Source sentences
Summary
Mean 7-month weight change from baseline in the full cohort was -4.1 kg (95% confidence interval: -5.0, -3.2; p < 0.001; -4.2%).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519401
02HumanObservational studyEfficacy outcome
In the full cohort of adults with obesity on liraglutide 3.0 mg, 40% lost at least 5% of body weight at 7 months.
In plain wordsIn adults with obesity on liraglutide, 40% had lost at least 5% of their body weight after 7 months.
Peptide
Liraglutide
Outcome
Not applicableProportion losing at least 5% of body weight at 7 months
Study
n = 277
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 7 monthsAs given in this study (human).
Measurements
Responders losing >=5% weight
40%
full cohort, 7 months
Source sentences
Summary
In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519405
03HumanObservational studyEfficacy outcome
In the full cohort of adults with obesity on liraglutide 3.0 mg, 14% lost more than 10% of body weight at 7 months.
In plain wordsIn adults with obesity on liraglutide, 14% had lost more than 10% of their body weight after 7 months.
Peptide
Liraglutide
Outcome
Not applicableProportion losing more than 10% of body weight at 7 months
Study
n = 277
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 7 monthsAs given in this study (human).
Measurements
Responders losing >10% weight
14%
full cohort, 7 months
Source sentences
Summary
In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519406
04HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, weight loss did not differ significantly between patients with and without a history of bariatric surgery.
In plain wordsIn adults with obesity on liraglutide, weight loss was not clearly different between people who had and had not had bariatric surgery.
Peptide
Liraglutide
Outcome
No significant changeWeight loss by history of bariatric surgery
Study
n = 277
Comparator
No history of bariatric surgery
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mgAs given in this study (human).
Source sentences
Summary
Weight loss did not differ significantly according to history of bariatric surgery (p = 0.94).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519407
05HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, diastolic blood pressure decreased from 87.0 to 83.9 mm Hg at 7 months.
In plain wordsIn adults with obesity on liraglutide, the lower blood pressure number fell from 87.0 to 83.9 mm Hg after 7 months.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure change at 7 months
Study
n = 277
Outcome group
Blood pressure · Cardiovascular
Studied dose
3.0 mg · 7 monthsAs given in this study (human).
Measurements
Diastolic blood pressure
87 to 83.9 mm Hg
7 months
Source sentences
Summary
Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; p = 0.018), with no significant changes in systolic blood pressure.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519408
06HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, systolic blood pressure showed no significant change.
In plain wordsIn adults with obesity on liraglutide, the upper blood pressure number did not change significantly.
Peptide
Liraglutide
Outcome
No significant changeSystolic blood pressure change at 7 months
Study
n = 277
Outcome group
Blood pressure · Cardiovascular
Studied dose
3.0 mg · 7 monthsAs given in this study (human).
Source sentences
Summary
Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; p = 0.018), with no significant changes in systolic blood pressure.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519409
07HumanObservational studyOther
In adults with obesity in a Swiss clinic, median persistence on liraglutide was 6.8 months.
In plain wordsIn adults with obesity in a Swiss clinic, people stayed on liraglutide for a median of 6.8 months.
Peptide
Liraglutide
Outcome
Not applicableMedian persistence on liraglutide
Study
n = 277
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
3.0 mgAs given in this study (human).
Measurements
Median persistence
6.8 months
full cohort
Source sentences
Summary
Median persistence on liraglutide was 6.8 months.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519410
08HumanObservational studyOther
In adults with obesity in a Swiss clinic, the median maximum liraglutide dose received was 1.5 mg.
In plain wordsIn adults with obesity in a Swiss clinic, the typical highest liraglutide dose was 1.5 mg, half of the 3.0 mg target.
Peptide
Liraglutide
Outcome
Not applicableMedian maximum dose received
Study
n = 277
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
1.5 mg (median maximum dose received)As given in this study (human).
Measurements
Median maximum dose
1.5 mg
full cohort
Source sentences
Summary
Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519411
09HumanObservational studyOther
In adults with obesity in a Swiss clinic, 13.7% of patients reached the liraglutide maintenance dose of 3.0 mg.
In plain wordsIn adults with obesity in a Swiss clinic, 13.7% of patients reached the 3.0 mg liraglutide maintenance dose.
Peptide
Liraglutide
Outcome
Not applicableProportion reaching the 3.0 mg maintenance dose
Study
n = 277
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
3.0 mgAs given in this study (human).
Measurements
Reached maintenance dose
13.7%
full cohort
Source sentences
Summary
Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519412
10HumanObservational studyEfficacy outcome
In adults with obesity who stayed on liraglutide 3.0 mg for at least 4 months, weight fell by 4.4 kg (4.7%) at 4 months.
In plain wordsIn adults with obesity who stayed on liraglutide for at least 4 months, weight fell by 4.4 kg at 4 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 4 months, persistent for at least 4 months
Study
n = 236
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 4 monthsAs given in this study (human).
Measurements
Weight change
−4.4 kg
persistent 4 months
Source sentences
Summary
Weight change was -4.4 kg (-4.7%) in the ≥4-month persistence subgroup at 4 months, -5.1 kg (-5.3%) in the ≥7-month persistence subgroup at 7 months, and -7.5 kg (-7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519402
11HumanObservational studyEfficacy outcome
In adults with obesity who stayed on liraglutide 3.0 mg for at least 7 months, weight fell by 5.1 kg (5.3%) at 7 months.
In plain wordsIn adults with obesity who stayed on liraglutide for at least 7 months, weight fell by 5.1 kg at 7 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 7 months, persistent for at least 7 months
Study
n = 159
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 7 monthsAs given in this study (human).
Measurements
Weight change
−5.1 kg
persistent 7 months
Source sentences
Summary
Weight change was -4.4 kg (-4.7%) in the ≥4-month persistence subgroup at 4 months, -5.1 kg (-5.3%) in the ≥7-month persistence subgroup at 7 months, and -7.5 kg (-7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519403
12HumanObservational studyEfficacy outcome
In adults with obesity who stayed on liraglutide 3.0 mg for at least 12 months, weight fell by 7.5 kg (7.1%) at 12 months.
In plain wordsIn adults with obesity who stayed on liraglutide for at least 12 months, weight fell by 7.5 kg at 12 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 12 months, persistent for at least 12 months
Study
n = 71
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 12 monthsAs given in this study (human).
Measurements
Weight change
−7.5 kg
persistent 12 months
Source sentences
Summary
Weight change was -4.4 kg (-4.7%) in the ≥4-month persistence subgroup at 4 months, -5.1 kg (-5.3%) in the ≥7-month persistence subgroup at 7 months, and -7.5 kg (-7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients' persistence on treatment, in a real-world setting.
Summary · context
Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71).
Report a problemFND-3451519404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.